Literature DB >> 20663842

De novo infantile primary antiphospholipid antibody syndrome.

J Alshekaili1, G Reynolds, M C Cook.   

Abstract

Most autoimmune diseases are rare in infants. Early onset can represent an extreme phenotype arising from strong genetic predisposition relatively independent of environmental influence. Alternatively, neonatal autoimmunity can arise from transplacental passage of maternal pathogenic IgG autoantibodies. Distinguishing between these possible explanations is crucial for determining the prognosis in the specific patient, and has important implications for understanding pathogenesis. We report a case of neonatal thrombotic stroke associated with both cardiolipin and β2-glycoprotein I antibodies in neonatal serum but absent from cord blood and maternal serum. While the child also carried one prothrombotic allele of factor V (Leiden allele), which may have contributed to the risk of thromboembolic disease, the serological analysis represents unequivocal evidence of de novo neonatal primary phospholipid antibody syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20663842     DOI: 10.1177/0961203310375263

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  3 in total

1.  Neonatal stroke associated with de novo antiphospholipid antibody and homozygous 1298C/C methylenetetrahydrofolate reductase mutation.

Authors:  Paulo Rego Sousa; Ricardo Figueira; Rui Vasconcellos
Journal:  BMJ Case Rep       Date:  2012-11-15

Review 2.  Clinical, laboratory, and therapeutic analyses of 21 patients with neonatal thrombosis and antiphospholipid antibodies: a literature review.

Authors:  Marcus Vinicius da Costa Peixoto; Jozélio Freire de Carvalho; Carlos Ewerton Maia Rodrigues
Journal:  J Immunol Res       Date:  2014-07-17       Impact factor: 4.818

3.  Case Report: Infantile Ischemic Stroke and Antiphospholipid Antibodies, Description of Four Cases.

Authors:  Teresa Giani; Angela Mauro; Giovanna Ferrara; Rolando Cimaz
Journal:  Front Pediatr       Date:  2020-11-24       Impact factor: 3.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.